Aridis Pharmaceuticals, Inc. filed its 10-K on May 22, 2023 for the period ending Dec 31, 2022. In this report its auditor, Baker Tilly, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.059 USD | -5.60% | 0.00% | -15.83% |
1st Jan change | Capi. | |
---|---|---|
-15.83% | 2.83M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.22% | 22.48B | |
-9.49% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- ARDS Stock
- News Aridis Pharmaceuticals, Inc.
- Aridis Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt